Equities researchers at StockNews.com started coverage on shares of CASI Pharmaceuticals (NASDAQ:CASI – Get Free Report) in a report issued on Thursday. The firm set a “hold” rating on the biotechnology company’s stock.
CASI Pharmaceuticals Price Performance
Shares of CASI Pharmaceuticals stock opened at $3.61 on Thursday. The firm has a fifty day moving average price of $5.19 and a 200 day moving average price of $4.84. CASI Pharmaceuticals has a 1 year low of $1.85 and a 1 year high of $8.48. The stock has a market cap of $48.29 million and a PE ratio of -1.20.
Institutional Inflows and Outflows
Several institutional investors have recently made changes to their positions in CASI. Citigroup Inc. purchased a new position in shares of CASI Pharmaceuticals during the first quarter worth $59,000. Virtu Financial LLC grew its position in CASI Pharmaceuticals by 39.6% during the first quarter. Virtu Financial LLC now owns 112,777 shares of the biotechnology company’s stock valued at $91,000 after buying an additional 31,971 shares during the period. Susquehanna International Group LLP grew its position in CASI Pharmaceuticals by 70.6% during the fourth quarter. Susquehanna International Group LLP now owns 57,395 shares of the biotechnology company’s stock valued at $100,000 after buying an additional 23,758 shares during the period. Finally, Renaissance Technologies LLC acquired a new stake in CASI Pharmaceuticals during the third quarter valued at $27,000. Hedge funds and other institutional investors own 22.23% of the company’s stock.
CASI Pharmaceuticals Company Profile
CASI Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma.
See Also
- Five stocks we like better than CASI Pharmaceuticals
- About the Markup Calculator
- 3 Value Stocks Too Small For Buffett’s Portfolio
- How Investors Can Find the Best Cheap Dividend Stocks
- Foot Locker Builds Up Another Head of Steam; Gains Imminent
- Find and Profitably Trade Stocks at 52-Week Lows
- Disney Stock Catches 3 Upgrades In a Single Week
Receive News & Ratings for CASI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CASI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
